Beaconcure Raises $14 Million Series B to Expand AI-powered Clinical Technology Platform
Summary
Verify is the industrys first independent platform of its kind, implemented by many of the top 10 pharmaceutical companies and Contract Research Organizations (CROs) to reduce their data verification timelines from months to days while identifying potentially catastrophic errors in the process.We are humbled and proud to be supported by our new lead investor, chairman and world-class team of strategic advisory members, said Yoran Bar, co-founder and CEO of Boston-based Beaconcure. Beaconcure has proven its ability to accelerate clinical trial timelines, delivering on its promise of helping its partner companies bring therapies to patients faster. The companys unrelenting focus on providing real value to its pharmaceutical customers makes it an ideal partner for NewVale.Rick Riegel, incoming Chairman of the Board, said, To-date, there has been an unaddressed gap in the clinical trial data-management process in our industry. Until Beaconcures innovative software product was introduced, there had been little focus on tools that can make the analysis and validation stage a secure, streamlined, consistent process. Faced with growing regulatory scrutiny, the industry now can move with greater speed and confidence.In addition to Mr. Riegel, Beaconcure is pleased to announce the appointment of its Strategic Advisory Board, which includes industry visionaries across clinical development, biostatistics and regulatory areas: Craig Lipset: Former Head of Clinical Innovation at Pfizer and an advisor to technology and biopharmaceutical companies, leading universities, and the venture community.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
